LifEscozul Group

LifEscozul Group is a biotechnology company specializing in the research and development of Escozul, a therapeutic formulation derived from the venom of the blue scorpion (Rhopalurus junceus). The company focuses on providing personalized cancer treatments and conducting scientific studies to validate the anti-tumor properties of the venom. LifEscozul operates through a network of medical professionals and researchers across Latin America and Europe, aiming to standardize the production and administration of scorpion venom-based therapies. Their services include medical monitoring, dosage adjustment, and ongoing clinical observation for patients with various types of malignant tumors.